Background {#Sec1}
==========

Neonatal bacterial meningitis has high rates of mortality and morbidity in Europe and North America, and higher still in Africa and Asia \[[@CR1]\]. The symptoms and signs are non-specific in neonates, and the diagnosis can only be confirmed by analysing cerebrospinal fluid (CSF), following lumbar puncture (LP). Infants with meningitis typically require 14--21 days of inpatient intravenous antibiotics, incurring significant financial costs, and often receive hospital follow-up due to the risk of long-term neurological sequelae \[[@CR2]\]. Prolonged antibiotic use is associated with significant complications \[[@CR3], [@CR4]\]. If meningitis can be excluded, antibiotics are usually stopped after 5 days, allowing discharge with no further follow-up.

Each year up to 30,000 UK newborn infants undergo LP \[[@CR5]\], but success rates are much lower in neonates (50--60%) \[[@CR6], [@CR7]\] than older children (78--87%) \[[@CR8], [@CR9]\]. Interpretation of non-clear CSF samples containing significant numbers of red blood cells (RBC) (\> 5000, or \> 10,000 RBC/mm^3^) is challenging and the presence/absence of meningitis difficult to confirm. Thus, LPs often need repeating, and lead to treatment with extended courses of antibiotics because meningitis cannot be excluded.

LP techniques currently vary by local practice. Several modifications to 'traditional' technique have been investigated, but few have good evidence of benefit. Two modifications identified during a literature review appeared the most promising and amenable to investigation in an RCT: Sitting position, in which the infant is held in a semi-upright, sitting position compared to lying ('lateral decubitus') position.'Early stylet removal' (ESR), which is the removal of the stylet from the LP needle shaft once it has penetrated the subcutaneous tissue, and before advancing the needle into the CSF.

Sitting: the only published systematic review regarding LP in children/neonates examined sitting position and concluded that "Positions other than the lateral decubitus may be equal or superior in terms of lumbar puncture success" ...and... "A large-scale prospective clinical trial directly addressing LP success and safety in different positions would clarify the need to change current practice" \[[@CR10]\].

Stylet removal: traditional technique aims to insert the needle into the CSF space, before removing the stylet ('late stylet removal' (LSR)). If the needle has advanced too far, unintentional puncture of the anterior venous plexus can cause a blood-stained tap. ESR has therefore been adopted by some practitioners but is only backed by observational evidence \[[@CR8], [@CR9]\].

Other literature suggests no consistent evidence of significant benefit for: training in LP \[[@CR11], [@CR12]\]; seniority of practitioner \[[@CR8], [@CR9], [@CR13]--[@CR16]\]; sedation \[[@CR13], [@CR17]\]; local anaesthetic \[[@CR8], [@CR9], [@CR12], [@CR15], [@CR18], [@CR19]\]; and formulae for needle insertion depth (except certain subgroup analyses) \[[@CR20]\]. Although there is growing evidence for ultrasound assistance \[[@CR21]--[@CR25]\], the equipment and training required has hindered widespread adoption. In comparison, sitting position and ESR are straightforward and already used by some practitioners.

Aims {#Sec2}
----

We aim to determine the optimal technique for lumbar puncture in newborn infants by evaluating the success rate, short-term clinical, resource, and safety outcomes of two modifications to traditional LP technique: infant position (sitting vs lying) and timing of stylet removal (early vs late).

This would be the first appropriately-powered RCT investigating neonatal LP technique and would therefore make a significant contribution to current knowledge.

Methods/design {#Sec3}
==============

Aim & Design {#Sec4}
------------

This is a pragmatic, multicentre, 2 × 2 factorial RCT to compare the proportion of infants with CSF obtained and RBC count \< 10,000/mm^3^ on the first LP procedure when sitting position is adopted compared to lying position, and when ESR is performed compared to LSR. Other clinical decisions will be made according to local protocols. Clinicians undertaking LPs will receive training in the different trial techniques. Once a decision is made to perform an LP as part of routine care, parents of eligible infants will be approached to discuss consent. If given, randomisation will proceed. Staff will be advised to undertake 1--2 attempts (defined as the needle passing through the skin once) per 'procedure'. The randomised technique will be used for up to two procedures. The requirement and timing for a second or any further procedures will be determined by the clinical team. Data will be collected from hospital records, and recorded on trial specific electronic case report forms (eCRFs). All samples sent to the laboratory will follow local site procedures, with relevant data from the laboratory reports inputted onto eCRFs. The trial rationale and design were closely discussed with and received input from local parent representatives from the local Support for the Sick Newborn And their Parents (SSNAP) charity \[[@CR26]\].

The trial includes an internal pilot, which was based in centres recruiting the first 250 randomised infant participants in the first 8 months, in order to optimise study processes around recruitment, intervention delivery, training, and outcome assessments. The Trial Steering Committee (TSC) reviewed pilot data and have made recommendations and approved continuation.

The trial design is summarised in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Study flowchart

Setting & participants {#Sec5}
----------------------

Infants who are having an LP in UK neonatal units and their maternity wards.

Inclusion criteria {#Sec6}
------------------

Parent(s) willing and able to give informed consentInfants of corrected gestational age (CGA) from 27^+ 0^ weeks to 44^+ 0^ weeks, AND working weight of 1000 g or moreFirst LP for current indication

Exclusion criteria {#Sec7}
------------------

Unable to be held in sitting position (including infants intubated and mechanically-ventilated) or other clinical condition which is likely, in the opinion of the treating clinician, to make sitting difficult, or which is likely to be compromised by sitting (e.g. open gastroschisis).Previously randomised to the trial

Schedule of study procedures {#Sec8}
----------------------------

TasksVisitsScreeningFirst LPFurther LPs (if needed)DischargeEligibility confirmedXInformed consentXRandomisationXSTAI-S (Parent Questionnaire)^a^XXData collection to eCRFXXXXSerious/Adverse Event assessmentsXX^a^Internal pilot sites to complete following consent (before first LP) and within 48 h after first LP

Primary outcome {#Sec9}
---------------

The proportion of infants with successful first LPs (RBC count fewer than 10,000/mm^3^ in CSF on first procedure).

Secondary outcomes {#Sec10}
------------------

The following short-term clinical, resource and safety outcomes have been defined as: The proportion of infants with: No CSF obtained, or pure blood/clotted, or blood-stained, or clearCSF obtained and RBC count \< 500, \< 5000, \< 10,000, or \< 25,000 /mm^3^, or any RBC countA CSF white blood cell (WBC) count not requiring a correction (whatever the RBC count)Total number of procedures and attempts performed per infantProportion of infants diagnosed (by WBC count criteria, culture, Gram stain, and/or clinically) via CSF with: Meningitis: WBC count 20 or more in CSF, or a true positive culture/Polymerase Chain Reaction (PCR) (if RBC count is ≥500, the WBC count will be reduced by 1 for every 500 RBC counts to give a 'corrected' WBC count)Equivocal: WBC count (or corrected WBC) \< 20, AND negative (or contaminated/incidental) culture and PCR with: Either Polymorphonuclear leukocytes (PMN) \> 2 (and RBC count \< 500)OROrganism found on Gram stainNegative: WBC (or corrected WBC) count \< 20, PMN ≤2 (if RBC count \< 500), and negative (or contaminated/incidental) cultures, PCR, and Gram stainUninterpretable: No CSF obtained, or clotted, or CSF so bloody or insufficient that a cell count was impossibleCSF WBC, RBC, corrected WBC counts, PMNs and lymphocytes from the clearest sampleTime taken on first procedure from start of cleaning skin to removing needle at end of all attemptsInfant movement on first procedure using a basic 4-point scale

Outcomes related to cost and safety {#Sec11}
-----------------------------------

In all infants, according to CSF-defined and clinically-defined diagnostic criteria: Duration of the antibiotic courseLength of stay in surviving infantsImmediate complications related to LP: Cardiovascular instability, including oxygen saturations and heart rateRespiratory deterioration (escalating respiratory support) post-LPFor the pilot phase: parental anxiety (State Trait Anxiety Inventory - State Subscale (STAI-S) Questionnaire)

Screening and recruitment {#Sec12}
-------------------------

Infants who are having an LP will be screened for eligibility. Anonymised screening data will be recorded via the randomisation website for the Coordinating Centre to review rates of ineligibility and participant uptake rates.

Parents of eligible infants will be provided with both verbal and written information in a Parent Information Leaflet by their clinical team. Parents with legal parental responsibility will be approached to discuss the trial, answer any questions they may have and to request consent. Parents will have as much time as they need to consider and discuss the information with the research team, or other independent parties to decide whether to participate in NeoCLEAR. Written informed consent for the study will be obtained by a suitably qualified member of the study team. Parents completing the STAI-S will also be asked to provide written consent for their participation. Consent will be given at such time to allow randomisation and enable the clinical team to prepare for that procedure. Where this is not possible, the LP will not be delayed if the infant's clinician deems any delay to be clinically unsound: in such cases, the infant would not be recruited to NeoCLEAR.

Randomisation and blinding {#Sec13}
--------------------------

Infants will be randomised 1:1:1:1 to one of the four arms: (1) Lying (lateral decubitus) position and LSR; (2) Lying position and ESR; (3) Sitting position and LSR, or (4) Sitting position and ESR, using a 24/7 secure web-based randomisation facility which will ensure balance between the groups. A telephone backup system will be available 24 h a day.

Stratified block randomisation will be used to ensure balance between the groups with respect to the collaborating hospital and CGA at trial entry (four groups: 27^+ 0^--31^+ 6^/32^+ 0^--36^+ 6^/37^+ 0^--40^+ 6^/41+ weeks). Where repeat (second) LPs are warranted, they will receive the same allocated technique. Multiple births will be randomised separately with their study ID numbers linked on the database prior to analysis.

A statistician independent of the trial will generate the randomisation schedule and the Senior Trials Programmer will write the web-based randomisation program; both will be independently validated. The implementation of the randomisation procedure will be monitored by the Senior Trials Programmer throughout the trial and reports will be provided to the Data Monitoring Committee (DMC).

This is an open-label trial as blinding of the practitioner and nursing staff to the allocated technique is not possible. The assessment of the primary outcome and major secondary outcomes will be based on laboratory tests (effectively blinded). Parents will not usually be told which technique their infant has been allocated, and are not routinely present for the procedure; however if they request this, it will be shared with them and they may observe the LP at the discretion of the practitioner.

Baseline assessments {#Sec14}
--------------------

Trial entry data will include details to confirm eligibility and confirmation of parental written consent. During the pilot phase, after consent but before the first LP, the parent was asked to complete a 5-point Likert scale 'How have you felt physically during the last couple of days?', and STAI-S questionnaire \[[@CR27], [@CR28]\]. STAI-S is a well-validated measure consisting of 20 questions that identify how stressed/anxious someone is feeling at the time of assessment. All items are rated on a 4-point scale, the mean score will be used in analyses. Discontinuation of the STAI-S was recommended by the TSC based on a review of the pilot.

Subsequent data collection {#Sec15}
--------------------------

Most outcome data for this trial are routinely recorded clinical items obtained from the clinical notes. Non-routinely collected data includes procedural details such as time taken, infant movement, oxygen saturation and heart rate. No additional blood or tissue samples are required for this trial. All data will be collected using trial specific eCRFs. Outcome data will be collected until discharge home. Parents completing the STAI-S will be asked to complete a second questionnaire within 48 h following the first LP.

Sample handling {#Sec16}
---------------

As per best practice, all samples from any attempt should be sent to the microbiology laboratory for standard lab analyses, even if bloody or only 1--3 drops obtained, as culture may be informative.

Description of procedure {#Sec17}
------------------------

Participating infants will require LP as part of routine care; NeoCLEAR randomisation will specify the technique used. Training will attempt to standardise other potential confounders, including needle type and analgesia. Practitioners will be trained and given written best practice guidance on technique, including recommendations for LP variables. However, adherence will not be mandatory, and will be captured in the trial eCRFs.

The first LP should be performed within the same shift as randomisation where possible, to minimise bias, in 1--2 attempts. If a second LP is required, the same technique should be employed. The need for any further procedures will be determined by the consultant.

Safety reporting {#Sec18}
----------------

An independent DMC will be established to review the study data and outcomes including safety reports of Serious Adverse Events (SAEs). The DMC will ensure the safety and wellbeing of the trial participants and make recommendations to the TSC regarding continuance of the study or modification of the protocol. The TSC will have ultimate responsibility for deciding whether the trial should be stopped on safety grounds. SAEs will be collected until the infant is discharged home, as SAEs occurring after this time point should not relate to the trial intervention. As parental participation is limited to the STAI-S questionnaire, no SAE recording will be conducted for this group.

The following are known, but rare, complications of LP: any occurrence following the LP should be reported as an SAE: Iatrogenic meningitisIatrogenic haemorrhage: spinal haematoma (symptomatic), intraventricular, intracerebral and subarachnoid haemorrhageCerebral herniationNerve damage

The full protocol and Guidance Sheets provided to sites also pre-specify expected SAEs that are foreseeable in the trial population, and will not be reported unless thought to be causally related to trial procedures.

All unforeseeable SAEs occurring after consent until discharge home must be reported.

Discontinuation and withdrawal {#Sec19}
------------------------------

Parents have the right to withdraw consent for any aspect of the study, including their infant's future procedures and data collection, or their own questionnaire completion. The treating clinician may discontinue a participant if they consider it to be in the best interests of the infant's health and wellbeing.

Definition of end of study {#Sec20}
--------------------------

The end of the trial will be defined as the date when the trial database is locked. An end of trial declaration will be made to REC.

Project management {#Sec21}
------------------

The study is sponsored by the University of Oxford. The trial will be run by the NPEU CTU, based at the University of Oxford and the CI. On a day-to-day basis, the trial will be run by a Project Management Group (PMG) according to NPEU CTU SOPs and will be subject to audit and inspection. The core PMG will meet every month, either remotely or face-to-face. An extended PMG (Co-Investigator Group) will meet regularly to troubleshoot, review progress and forward plan. The PMG reports to the TSC.

The trial will be overseen by the TSC which will have ultimate responsibility for considering and, as appropriate, acting on the recommendations of the DMC. The TSC will include an independent chair, at least one clinician, statistician and Patient and Public Involvement (PPI) representative, and the CI. The TSC will meet at least annually and review the progress of the trial.

The DMC will be independent of the study and the TSC. The DMC will review the progress of the trial and interim analysis at least annually, and make recommendations on the conduct of the trial to the TSC.

Patient and public involvement {#Sec22}
------------------------------

Patient and public representatives have been extensively involved in trial planning, grant/protocol writing, and preparing study materials. Advice from two PPI co-applicants from local charity SSNAP \[[@CR26]\] included aspects of protocol design, wording in parent-facing documentation, as well as ongoing recruitment initiatives. Contributions on documentation were also received from Bliss baby charity \[[@CR29]\]. A lay person is a member of the TSC, and will be involved in trial oversight and dissemination of findings.

Statistics and analysis {#Sec23}
-----------------------

### Sample size and power calculation {#Sec24}

Four hundred eighty-three infants are required for each arm of the main comparison (sitting vs lying position and ESR vs LSR), to detect a 10% absolute difference (from 59 to 69%) in the proportion of infants with successful LPs, with 90% power, a 5% two-sided significance level and assuming (based on expert opinion and the lack of external evidence) no interaction effect between infant position and timing of stylet removal. Allowing for 5% attrition, the required recruitment target is 1020 (255 in each of the four groups). The 59% control event rate was derived from local prospective cohort data \[[@CR30]\] and corroborated by published UK data \[[@CR20]\]. We estimate 50% parental uptake rate and minimal 'loss to follow-up' as all data will be collected pre-discharge.

Modelling suggests we will need 10 local Neonatal Units and Neonatal Intensive Care Units to recruit enough infants within 24 months, with a recruitment rate of around 5 infants per centre per month assuming: staggered starts (two centres per month), and each centre taking 4 months to reach stable recruitment rate. PMG will implement recruitment initiatives and additional centres, based on actual recruitment.

Our inclusion/exclusion criteria are designed to minimise protocol deviations by only including infants who can be sat up. Only sparse safety data is available for LPs \< 27 weeks and \< 1000 g; hence these infants will be excluded from our trial.

### Description of statistical methods {#Sec25}

Outcomes for participants will be analysed in the groups to which they are assigned regardless of deviation from the protocol or allocation received, but will be excluded from the analysis if no LP procedure was received (modified intention-to-treat analysis). To assess the effect of position we will compare groups (1--Lying/LSR) plus (2--Lying/ESR) with groups (3--Sitting/LSR) plus (4--Sitting/ESR), and to assess the effect of the timing of stylet removal we will compare groups (1) plus (3) with groups (2) plus (4). We will calculate the risk ratio (95% Confidence Interval (CI)) for the primary outcome (and all other dichotomous outcomes), the mean difference (95% CI) for normally distributed continuous outcomes or the median difference (95% CI) for skewed continuous outcomes. Absolute risk difference and CIs will also be calculated for tested dichotomous clinical outcomes (to be presented in a supplementary appendix). Groups will be compared using regression analysis, adjusting for the stratification variables used at randomisation. Both crude and adjusted estimates will be presented but the primary inference will be based on the adjusted analyses. Adjusted risk ratios will be estimated using log-binomial regression, or a Poisson regression model with a robust variance estimator in the event of non-convergence. Linear regression will be used for normally distributed outcomes and quantile regression for skewed continuous outcomes.

With a view to minimising the effects of multiple testing given the number of procedures and attempts performed for each infant, and correlation between some outcomes, statistical inference will be restricted to a predefined list of tested outcomes. Summary data by trial arm will be provided for all other outcomes but statistical tests (or the calculation of CIs) will not be performed. A complete list of outcomes that will be tested and not tested statistically are provided in a supplementary appendix.

Full details of the statistical analysis will be documented in the Statistical Analysis Plan.

### Interaction testing {#Sec26}

The interaction between sitting/lying position and the timing of stylet removal will be investigated for the primary outcome, though we acknowledge that the trial is not powered to detect an interaction effect. A descriptive multi-arm analysis will also be presented for the primary outcome, other tested outcomes, and baseline characteristics (i.e. for each of the four trial arms) as supplementary information \[[@CR31]\].

### Interim data monitoring {#Sec27}

Interim data monitoring will be carried out by the DMC at least annually. The DMC Charter will include details about timings of reviews, contents of the reports and any stopping guidelines.

Discussion {#Sec28}
==========

Participant risks and benefits {#Sec29}
------------------------------

All trial participants will be having an LP as part of routine clinical care. All techniques are in current use and none is proven to be more or less safe than another. No infants are expected to be placed at risk as a result of being in the trial. Serious complications of LP are rare. Some complications can be prevented by avoiding LPs in infants with contraindications such as coagulopathy; or mitigated, e.g. with sterile technique. Potential benefits of trial participation include: an optimised analgesia protocol; all infants will have heart rate and oxygen saturations monitored during the procedure.

Parent questionnaire {#Sec30}
--------------------

Parents completing the STAI-S questionnaire will be asked about their feelings and levels of anxiety which are sensitive and upsetting topics. Our PPI group and previous research has indicated that in stressful situations, parents benefit from being given the opportunity to express their feelings. Completion of the questionnaire will not be pursued if a parent becomes distressed when completing it.

Consent {#Sec31}
-------

Ideally, consent will be given at such time to allow randomisation and enable the clinical team to prepare for that procedure. However, in instances where this is not possible, the LP will not be delayed if, in the opinion of the infant's clinician, any delay would be deemed clinically unsound: in such cases, the infant would not be recruited to the trial.

Participant confidentiality {#Sec32}
---------------------------

The infants' and parents' names will be shared with NPEU CTU via the consent form. Parents of infants participating in the trial will be informed of, and provide consent to this. No other personal identifiable information will be shared outside of the site.

Overall responsibility for ensuring that each participant's information is kept confidential lies with the Sponsor. All paper documents will be stored securely and kept in strict confidence in compliance with current data regulations. Data collected on the (e)CRFs will be stored in an electronic database held by the Trial Coordinating Centre in which the participant will be identified only by a trial specific number.

Following trial completion and report publication, data will be archived in a secure physical and electronic location with restricted access.

Participant remuneration {#Sec33}
------------------------

No financial or material incentive or compensation will be provided to parents for enrolling their infants in this trial.

Dissemination {#Sec34}
-------------

The success of the trial depends on a large number of research nurses, neonatal nurses, doctors, and parents. Credit for the trial findings will be given to all who have collaborated and participated in the trial including all local coordinators and collaborators, members of the trial committees, the NeoCLEAR Coordinating Centre and trial staff. Authorship at the head of the primary results paper will take the form "\[name\], \[name\] and \[name\] on behalf of the 'The NeoCLEAR Collaborative Group'". All contributors to the trial will be listed at the end of the main paper, with their contribution identified. It is the intention of the NeoCLEAR Collaborative Group to present data at national/international conferences and to publish open-access, peer-reviewed articles, including the analysis of key outcomes. The NPEU Clinical Trials Unit and local newborn charity will disseminate the results at conferences and coordinate press releases, website promotion, social and other media interest.

Supplementary information
=========================

 {#Sec35}

**Additional file 1.** Supplementary appendix: List of tested and untested outcomes.

CGA

:   Corrected gestational age

CSF

:   Cerebrospinal fluid

CTU

:   Clinical Trials Unit

DMC

:   Data Monitoring Committee

eCRFs

:   Electronic Case Report Forms

ESR

:   Early stylet removal

HRA

:   Health Research Authority

LP

:   Lumbar puncture

LSR

:   Late stylet removal

NIHR

:   National Institute for Health Research

NPEU

:   National Perinatal Epidemiology Unit

PCR

:   Polymerase Chain Reaction

PMNs

:   Polymorphonuclear Leukocytes

PPI

:   Patient and public involvement

RBC

:   Red Blood Cell(s)

RCT

:   Randomised controlled trial

REC

:   Research Ethics Committee

SAE

:   Serious Adverse Event

SSNAP

:   Support for the sick newborn and their parents

STAI-S

:   State-Trait Anxiety Inventory Subscale

TSC

:   Trial Steering Committee

WBC

:   White Blood Cell(s)
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Trial Steering Committee {#FPar1}
========================

The independent members of the TSC are Professor Paul Heath (Chair), Dr. Chris Gale (Vice-Chair), Professor Richard Elmsley, Ms. Marie Hubbard, Dr. Julie Nelson (PPI), Dr. Bill Yoxhall. The non-independent members are Associate Professor Charles Roehr and Associate Professor Edmund Juszczak.

Data Monitoring Committee {#FPar2}
=========================

The independent members of the DMC are Professor David Sweet (Chair), Professor Kate Costeloe and Professor Siobhan Creanor.

Declaration of Helsinki {#FPar3}
=======================

The Investigator will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki.

Guidelines for Good Clinical Practice {#FPar4}
=====================================

The Investigator will ensure that this study is conducted in accordance with relevant regulations and with Good Clinical Practice.

**Recruitment status** {#FPar5}
======================

Recruiting: at the time of submission for publication, participants are currently being recruited and enrolled to NeoCLEAR. Information regarding study sites can be found on the NeoCLEAR website \[[@CR32]\].

AM and CR conceived the idea for the study and wrote the initial protocol with clinical, scientific and methodological contributions from MS, JY, EA, LL, UB and EJ, and PPI input from CS and PS. CR is the Chief Investigator responsible for all aspects of the study, including preparation and submission of the grant application, securing funding, regulatory approvals, project management, data collection and preparation of the manuscript for publication. AS, UB and RW helped to design and refine the study, and develop the protocol. VC, JB, LL and EJ provided study design, statistical and methodological expertise, and RW contributed logistical aspects of the trial. All authors approved the final version of the manuscript.

This study is funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (15/188/106). The grant award process included peer-review of the protocol. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The funder provided advice and support and monitored study progress but did not have a role in study design or data collection, analysis and interpretation.

NeoCLEAR is sponsored by the University of Oxford. The contact on behalf of the sponsor for all correspondence relating to applications for this project is Clinical Trials & Research Governance, ctrg\@admin.ox.ac.uk.

Not applicable.

NeoCLEAR received approval from the NHS Health Research Authority, South Central Hampshire B Research Ethics Committee on 12 June 2018 (ref: 18/SC/0222, nrescommittee.southcentral-hampshireb\@nhs.net). Trust Confirmation of Capacity and Capability will be obtained at each site. The Chief Investigator or delegate will submit an Annual Progress Report, End of Study Notification, and Final Report to REC, HRA, host organisation and Sponsor.

Where necessary, approvals will be obtained from the above parties for all substantial amendments to the original approved documents, and disseminated by NPEU CTU to relevant parties.

Parents of eligible infants would be provided with both verbal and written information in the form of a Parent Information Leaflet, by their clinical team. Parent(s) with legal parental responsibility of eligible infants would be approached to discuss the trial further, answer any questions they may have, and to request consent. Parent(s) will have as much time as they need to consider the information, and the opportunity to question the research team, or other independent parties to decide whether they will participate in the study. Informed consent for the study will be obtained by a suitably qualified member of the study team. A parent must personally sign and date the latest approved version of the Informed Consent form before any study specific procedures are performed. For parents completing the STAI-S, they will also be asked to sign and date the consent form to agree to participate themselves.

Not applicable.
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